<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Parry, Nicola</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Toth, Peter P.</style></author><author><style face="normal" font="default" size="100%">Giugliano, Robert P.</style></author><author><style face="normal" font="default" size="100%">Gitt, Anselm Kai</style></author><author><style face="normal" font="default" size="100%">Cesena, Fernando H.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Advances in the Management of Low-Density Lipoprotein Cholesterol</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-10-27 11:20:52</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">12-14</style></pages><abstract><style  face="normal" font="default" size="100%">This article highlights select advances in the intensive management of low-density lipoprotein cholesterol levels. It discusses the use of statins as the cornerstone of treatment, addresses the use of novel adjuvant therapies for reducing atherogenic lipoproteins, and highlights data from important new studies demonstrating the safety and clinical impact of much more aggressive low-density lipoprotein cholesterol reduction in patients with established coronary artery disease.</style></abstract><number><style face="normal" font="default" size="100%">28 suppl 1</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>